Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Total Current Liabilities (2016 - 2025)

INVO Fertility (IVF) has disclosed Total Current Liabilities for 15 consecutive years, with $9.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 6.81% to $9.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.2 million, a 6.81% increase, with the full-year FY2024 number at $17.9 million, up 124.0% from a year prior.
  • Total Current Liabilities was $9.2 million for Q3 2025 at INVO Fertility, down from $12.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $18.7 million in Q1 2025 to a low of -$69489.0 in Q1 2023.
  • A 5-year average of $6.0 million and a median of $4.3 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: plummeted 106.9% in 2023, then skyrocketed 12762.15% in 2024.
  • INVO Fertility's Total Current Liabilities stood at $1.2 million in 2021, then surged by 184.2% to $3.3 million in 2022, then soared by 139.75% to $8.0 million in 2023, then soared by 124.0% to $17.9 million in 2024, then plummeted by 48.43% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for IVF's Total Current Liabilities are $9.2 million (Q3 2025), $12.5 million (Q2 2025), and $18.7 million (Q1 2025).